Despite the potential of CHK1 inhibitors, there are several challenges associated with their use. One major challenge is the development of resistance mechanisms within tumor cells, which can involve upregulation of alternative DNA damage response pathways or mutations in the CHK1 gene itself. Another challenge is the potential toxicity to normal tissues, which requires careful dosing and combination strategies to minimize side effects while maximizing therapeutic efficacy.
